ArticleNature communications2022
Nanoparticle-based modulation of CD4
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Real-time multimodal phenotyping reveals distinct tumour cell dynamics and immune escape mechanisms in T cell therapies.Nature biomedical engineering · 2026Article
- Innate Immune-Cloaked Microgel-Coated Mesenchymal Stromal Cells Reverse Persistent Pulmonary Fibrosis via Reparative Macrophages.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Beyond the Th2 paradigm: CD4+ cytotoxic T lymphocytes as key drivers of tissue damage and fibrosis in IgG4-related disease.Frontiers in immunology · 2026Review
- Nanotechnology for CAR T cells and tumour-infiltrating lymphocyte therapies.Nature nanotechnology · 2025Review
- [Biomaterials of different sizes for enhanced adoptive cell transfer therapy in solid tumors].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Comprehensive analysis of m6A-related lncRNAs as prognosis factors in the immune microenvironment of colorectal cancer.Journal of gastrointestinal oncology · 2025Article
- Review
- Alginate-based artificial antigen presenting cells expand functional CD8Biomaterials · 2025Article
- Article
- Nanoengineered-based delivery systems to modulate CD4Frontiers in pharmacology · 2025Review
- Ex vivo expansion and hydrogel-mediated in vivo delivery of tissue-resident memory T cells for immunotherapy.Science advances · 2024Article
- Nanomedicine for cancer patient-centered care.MedComm · 2024Review
- Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy.Nanoscale · 2024Review
- Immunotherapy Study on Non-small-Cell Lung Cancer (NSCLC) Combined with Cytotoxic T Cells and miRNA34a.Molecular pharmaceutics · 2024Article
- Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering.Immuno-oncology technology · 2024Review
- Genetically engineered CD80-pMHC-harboring extracellular vesicles for antigen-specific CD4Frontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Ariel IsserDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Aliyah B SilverJohns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Hawley C PruittDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, 21287, USA.ORCID 0000-0002-8189-5031
Michal MassDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Emma H EliasDepartment of Biology, Johns Hopkins University Krieger School of Arts and Sciences, Baltimore, MD, 21287, USA.
Gohta AiharaDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID 0000-0002-2492-9610
Si-Sim KangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID 0000-0001-9448-447X
Niklas BachmannDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID 0000-0001-8169-1592
Ying-Yu ChenDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Elissa K LeonardDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Joan G BielerJohns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Worarat ChaisawangwongJohns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Joseph ChoyJohns Hopkins Translational ImmunoEngineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID 0000-0001-6282-9437
Sydney R ShannonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Sharon GerechtDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Jeffrey S WeberLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, USA.
Jamie B SpanglerDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID 0000-0001-8187-3732
Jonathan P SchneckDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. jschnec1@jhmi.edu.ORCID 0000-0001-5346-2776
Johns Hopkins University · USNYU Langone Health · US
Funding
Training: Molecular & Cellular Bases of Infectious DiseasesT32AI007417 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Arturo Casadevall · 1994 to 2026
$11.9MTR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jamie Berta Spangler · 2019 to 2026
$11.5MThe Role of Physical Cues in Collective Cell InvasionU54CA210173 · NCI · JOHNS HOPKINS UNIVERSITY · PI WIRTZ, DENIS · 2016 to 2020
$9.9MT32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer ResearchT32CA153952 · NCI · JOHNS HOPKINS UNIVERSITY · PI Denis Wirtz · 2015 to 2026
$3.5MUse of aAPC for Melanoma Adoptive ImmunotherapyR01CA108835 · NCI · JOHNS HOPKINS UNIVERSITY · PI SCHNECK, JONATHAN P · 2004 to 2015
$3.3MBiomimetic Matrix for Ex Vivo and In Vivo Activation of T CellsR01EB029341 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI MAO, HAI-QUAN, SCHNECK, JONATHAN P · 2020 to 2023
$1.9MImmunoengineered nanotechnology for targeted expansion of regulatory T cellsR01EB029455 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA · 2020 to 2023
$1.7MA high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cellsR33CA229042 · NCI · JOHNS HOPKINS UNIVERSITY · PI SCHNECK, JONATHAN P · 2019 to 2021
$1.4MOPTIMIZING THE PRE-CLINICAL DEVELOPMENT OF IMMUNOTHERAPEUTIC ANTIBODIES THROUGH GLYCOENGINEERINGR21CA249381 · NCI · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA, YAREMA, KEVIN J · 2020 to 2021
$410kClass II artificial antigen presenting cells for cancer immunotherapyF31CA254121 · NCI · JOHNS HOPKINS UNIVERSITY · PI ISSER, ARIEL YOSEF · 2021 to 2022
$75kNCI NIH HHS F31 CA254121NCI NIH HHS R01 CA108835NCI NIH HHS R21 CA249381NCI NIH HHS R33 CA229042NCI NIH HHS T32 CA153952NCI NIH HHS U54 CA210173NIAID NIH HHS T32 AI007417NIBIB NIH HHS P41 EB028239NIBIB NIH HHS R01 EB029341NIBIB NIH HHS R01 EB029455U.S. Department of Health & Human Services | National Institutes of Health (NIH) P41EB028239U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01EB029341U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01EB029455U.S. Department of Health & Human Services | National Institutes of Health (NIH) R21CA249381U.S. Department of Health & Human Services | National Institutes of Health (NIH) R33CA229042U.S. Department of Health & Human Services | National Institutes of Health (NIH) U54CA210173
Abstract
Helper (CD4
Indexed as
Immunotherapy, AdoptiveNanoparticlesAnimalsAntigen-Presenting CellsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHLA AntigensHumansMiceHLA Antigens
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.